WHO recommends not using Remdesivir in the treatment of COVID-19 in hospitals – Medicines

The World Health Organization recommends that Remdesivir not be given to hospitalized patients with Covid-19, because this antiviral drug does not protect against death or severe forms of the disease, AFP reported.

“The antiviral drug Remdesivir is not recommended for patients admitted to hospital with Covid-19, regardless of the severity of the disease, because there is no evidence that it improves the chances of survival, or that it prevents the placement of a respirator “, said. says in a statement from the WHO.

The government is allocating more than 20 million BGN for vaccines against COVID-19 and remdesivir

The WHO said this after a team of experts published their findings in the medical journal BMG.

Experts emphasize that there is the possibility of serious side effects from the drug, BTA reported.

WHO advises against Gilead’s remdesivir for all hospitalized COVID-19 patients https://t.co/J1zhuDHwlF pic.twitter.com/oSHsWWNTlQ

– Reuters (@Reuters) November 20, 2020

Developed against Ebola, Gilliad’s laboratory sells this preparation under the trade name Vecluri.

On July 3, it became the first drug against Covid-19 approved in the European market.

Some time ago, the WHO said that only corticosteroids such as dextamethasone and hydrocortisone have been shown to be effective in treating severe forms of coronavirus infection, TASS reported.